Skip to main content

Table 1 The Relationship of PDEF expression alone and AR and PDEF co-expression with various clinicopathological parameters and other biomarkers in the 100 ER-negative breast cancer cases

From: AR–PDEF pathway promotes tumour proliferation and upregulates MYC-mediated gene transcription by promoting MAD1 degradation in ER-negative breast cancer

Variable PDEF expression (%) P value AR/PDEF expression (%) P value
Negative
40 (40.0)
Positive
60 (60.0)
AR+PDEF+
55 (55.5)
Others
45 (45.0)
Age
  ≤ 49 19 (36.5) 33 (63.5) 0.298 30 (57.7) 22 (42.3) 0.359
  > 49 21 (43.8) 27 (56.2) 25 (52.1) 23 (47.9)
Tumor size
  < 2 cm 12 (44.4) 15 (55.6) 0.841 14 (51.9) 13 (48.1) 0.803
 2~ 5 cm 18 (37.5) 30 (62.5) 29 (60.4) 19 (39.6)
  > 5 cm 10 (40.0) 15 (60.0) 12 (48.0) 13 (52.0)
Menopausal status
 No 18 (42.9) 24 (57.1) 0.385 22 (52.4) 20 (47.6) 0.403
 Positive 22 (37.9) 36 (62.1) 33 (56.9) 25 (43.1)
Grade
 1 5 (71.4) 2 (28.6) 0.032a 2 (28.6) 5 (71.4) 0.053
 2 17 (45.9) 20 (54.1) 18 (48.6) 19 (51.4)
 3 18 (32.1) 38 (67.9) 35 (62.5) 21 (37.5)
pTNM stage
 TNM I 12 (75.0) 4 (25.0) 0.011a 4 (25.0) 12 (75.0) 0.047a
 TNM II 21 (34.4) 40 (65.6) 37 (60.7) 24 (39.3)
 TNM III 7 (30.4) 16 (69.6) 14 (60.9) 9 (39.1)
Lymphatic metastasis
 No 34 (61.8) 21 (38.2) < 0.001a 22 (52.4) 20 (47.6) 0.403
 Positive 6 (13.3) 39 (86.7) 33 (56.9) 25 (43.1)
AR
 Negative 26 (83.9) 5 (16.1) < 0.001a
 Positive 14 (20.3) 55 (79.7)
PR
 Negative 36 (41.4) 51 (58.6) 0.341 46 (52.9) 41 (47.1) 0.211
 Positive 4 (30.8) 9 (69.2) 9 (69.2) 4 (30.8)
HER2
 Negative 8 (26.7) 22 (73.3) 0.058 21 (70.0) 9 (30.0) 0.039a
 Positive 32 (45.7) 38 (54.3) 34 (48.6) 36 (51.4)
Ki-67
  < 20% 7 (31.8) 15 (68.2) 0.263 14 (63.6) 8 (36.4) 0.250
  ≥ 20% 33 (42.3) 45 (57.7) 41 (52.6) 37 (47.4)
P53
 Negative 17 (33.3) 34 (66.7) 0.118 31 (60.8) 20 (39.2) 0.162
 Positive 23 (46.9) 26 (53.1) 24 (49.0) 25 (51.0)
VEGF
 Negative 12 (54.5) 10 (45.5) 0.092 10 (45.5) 12 (54.5) 0.218
 Positive 28 (35.9) 50 (64.1) 45 (57.7) 33 (42.3)
  1. aSignificantly different